Clinical Edge Journal Scan

Breast Cancer Radiation Therapy Raises Risk for Nonkeratinocyte Skin Cancer


 

Key clinical point: Patients with newly diagnosed breast cancer (BC) who underwent radiation therapy were at a significantly higher risk of developing nonkeratinocyte skin cancers, particularly melanoma and hemangiosarcoma.

Major finding: Compared with the general population, the risk for nonkeratinocyte skin cancer in the skin of the breast or trunk was 57% higher (standardized incidence ratio [SIR] 1.57; 95% CI 1.45-1.7) after BC treatment with radiation therapy, with a 1.37-fold higher risk for melanoma (SIR 1.37; 95% CI 1.25-1.49) and 27.11-fold higher risk for hemangiosarcoma (SIR 27.11; 95% CI 21.6-33.61).

Study details: This population-based cohort study included 875,880 patients with newly diagnosed BC from the Surveillance, Epidemiology, and End Results (SEER) database of which 50.3% of patients received radiation therapy.

Disclosures: This study did not declare any specific funding. Shawheen J. Rezaei declared being supported by Stanford University School of Medicine. Bernice Y. Kwong declared receiving personal fees from Novocure, Genentech, and Novartis. No other conflicts of interest were reported.

Source: Rezaei SJ, Eid E, Tang JY, et al. Incidence of nonkeratinocyte skin cancer after breast cancer radiation therapy. JAMA Netw Open. 2024;7(3):e241632 (Mar 8). doi: 10.1001/jamanetworkopen.2024.1632 Source

Recommended Reading

Oncologists Voice Ethical Concerns Over AI in Cancer Care
MDedge Hematology and Oncology
Do Real-World Data Support Omitting Sentinel Lymph Node Biopsy in Early Stage Breast Cancer?
MDedge Hematology and Oncology
No Routine Cancer Screening Option? New MCED Tests May Help
MDedge Hematology and Oncology
How Medicare Reimbursement Trends Could Affect Breast Surgeries
MDedge Hematology and Oncology
Is Axillary Surgery in Early Breast Cancer on Its Way Out?
MDedge Hematology and Oncology
De-Escalating Axillary Surgery Feasible in Breast Cancer with Sentinel-Node Metastases
MDedge Hematology and Oncology
Ribociclib + Nonsteroidal Aromatase Inhibitor Improves Prognosis in HR+/HER2− Early BC
MDedge Hematology and Oncology
High TIL Levels Linked to Improved Prognosis in Early TNBC Even in Absence of Chemotherapy
MDedge Hematology and Oncology
Novel Treatment Sequence Speeds Up Breast Reconstruction Procedures in Patients With Breast Cancer
MDedge Hematology and Oncology
MRI-Based Strategy Can Limit Neoadjuvant Chemotherapy Duration in HR−/HER2+ BC
MDedge Hematology and Oncology